Report
Patrik Ling
EUR 95.03 For Business Accounts Only

Vimian (Buy, TP: SEK40.00) - Soft start, but successful issue

Q1 sales and earnings disappointed, largely explained by Medtech (negative annual ordering programme (AOP) effects) and one-off costs. With the oversubscribed SEK1.63bn rights issue completed, Vimian has financing to execute on M&A opportunities near-term. We reinstate a recommendation with a BUY and SEK40 target price.
Underlying
VIMIAN GROUP AB

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Patrik Ling

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch